This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Renal MRA Crossover Study Comparing Multihance to Another Contrast Agent

This study has been completed.
Information provided by:
Bracco Diagnostics, Inc Identifier:
First received: December 22, 2006
Last updated: March 12, 2009
Last verified: March 2009
This is an explorative small pilot study comparing two MRA contrast agents, one of which has been on the market for a few years and the other fairly new to the market. Since the study is explorative and designed to provide preliminary information for consideration for a future larger study, sample size is not based on statistical assumptions.

Condition Intervention Phase
Steno-Occlusive Disease Drug: Multihance Drug: vasovist Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: A Pilot, Open-Label, Multicenter Intra-Individual Comparison of Multihance and Vasovist for Contrast-Enhanced Magnetic Resonance Angiography (CE-MRA) of Renal Arteries

Resource links provided by NLM:

Further study details as provided by Bracco Diagnostics, Inc:

Primary Outcome Measures:
  • Sensitivity and specificity compared to DSA [ Time Frame: post dose ]

Secondary Outcome Measures:
  • accuracy and predictive values; inter-reader agreement for diagnostic performance [ Time Frame: post dose ]

Enrollment: 39
Study Start Date: December 2006
Study Completion Date: February 2009
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Multihance
0.5 Molar, single injection at 0.2 mL/kg
Active Comparator: 2 Drug: vasovist
0.25 molar single injection 0.03 ml/kg


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Known or suspected renovascular disease based on one of the following criteria:

    • severe hypertension
    • hypertension refractory to standard therapy
    • abrupt onset of moderate to severe hypertension at age < 35 years
    • normalized blood pressure by an ACE inhibitor in a patient with moderate or severe hypertension
    • unexplained by stable elevation of serum creatinine > 2Mg/dL
    • positive findings for stenosis from another imaging modality
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00415805

Bracco Imaging, S.p.A
Milan, Italy, 20134
Sponsors and Collaborators
Bracco Diagnostics, Inc
Study Director: Gianpaolo Pirovano, MD Bracco Diagnostics
  More Information

Responsible Party: Gianpaolo Pirovano, M.D. Executive Director, Corporate Medical Development, Bracco Diagnostics Identifier: NCT00415805     History of Changes
Other Study ID Numbers: MH 128
Study First Received: December 22, 2006
Last Updated: March 12, 2009 processed this record on June 23, 2017